N4 Pharma: Turner Pope
(‘N4P’ ) has released positive results from the first in vivo study of its dual-loaded Nuvec® proof-of-concept (‘POC’) programme, N4 101, an orally delivered treatment for Inflammatory Bowel Disease (‘IBD’). Data indicates a sustained anti-inflammatory effect in a validated model through targeted treatment of nucleic acid therapeutics. This represents an important milestone in validating the Group’s novel delivery platform as it builds-out, enhances and advances its research with a view to positioning it as a platform of choice for gene therapy and cancer treatments. With a post raise cash runway expected to support it into H2 2026, in due course the Board looks forward to advancing this programme into its next phase of development, providing further updates on this and its broader platform work plans for the coming months. Recognising that drug development agreements will only ever be founded through provision of a comprehensive commercial data-room, these steps are key to fulfilling N4P’s 12-to-18-month objective of signing its first research collaboration(s) with a well-resourced industry player(s). Success here could then lead on to a number of remunerative platform licencing and milestone-based agreements for third party therapeutic projects. Given that the FDA now takes a product-focused, science-based approach to regulating nanotechnology products, there is potential for considerable value creation through adoption of N4P’s technology based on the operational advantages it brings and the absence of shortcomings (including off-target effects/immune responses) encountered through existing techniques.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.